| Centers for Disease Control and Prevention | mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-Cov-2 variants |
|---|---|
| FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine | COVID-19 vaccine reactions: The difference between common and allergic reactions |
| COVID-19 vaccines vs variants — Determining how much immunity is enough | Centers for Disease Control and Prevention |
|---|---|
| When vaccine is limited, who should get vaccinated first? FDA for emergency use authorization | Benefits of getting a COVID-19 vaccine |
| Centers for Disease Control and Prevention | How CDC is making COVID-19 recommendations |
|---|---|
| Centers for Disease Control and Prevention | Information about COVID-19 vaccines for people with allergies |
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
17